23andMe SPAC Presentation Deck

Our Scale Enables Real-Time Genetics Health Research 1,728,000 High cholesterol 1,572,000 Depression 986,000 Asthma 565,000 Irritable Bowel 479,000 Arrhythmia 7,700 Systemic Sclerosis 539,000 Type 2 Diabetes 1,260,000 APOE e4 carriers (Alzheimer's risk) 593,000 Atopic Dermatitis 96,000 UC / Crohn's 144,000 Coronary Artery 6,200 Sarcoidosis 29,000 Type 1 Diabetes 76,000 Epilepsy 225,000 Psoriasis 59,000 Barrett's Esophagus ¹ As of January 2021. 223and Me COVID-19 manuscript live on MedRXiv September 7, 2020. 38,000 Pulmonary Embolism 4,300 Idiopathic Pulmonary Fibrosis 1,100,000 COVID-19 study participants (January 2021) COVID-19 Research March 16 April 6 June 8 750K Consumers participated in the COVID-19 study in the first 90 days Sept. 7 Kicked Off Study Launched Study Preliminary Findings Printed Findings² 23andMe Confidential and Proprietary Information 23

View entire presentation